

Efficacy, safety and acceptability of a probiotic with *Bacillus coagulans* on immunomodulation in healthy volunteers: a randomized, double-blind, placebo-controlled pilot study

Submission date 06/11/2025	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 06/11/2025	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 06/11/2025	Condition category Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

This study looked at whether taking a daily probiotic supplement could help support the immune system and improve overall wellbeing in healthy adults. The probiotic being tested contains *Bacillus coagulans*, a type of friendly bacteria. Researchers also wanted to check how safe and acceptable the supplement is compared to a placebo (a capsule with no active ingredients).

Who can participate?

The study invited healthy men and women aged 18 to 65 who eat a balanced diet, exercise regularly, and don't have any long-term illnesses or immune-related conditions.

What does the study involve? (for participants)

People who joined the study were randomly given either the probiotic or a placebo capsule to take once a day for 90 days. They visited the clinic twice—once at the start and once at the end of the 90 days. At each visit, a small blood sample was taken to measure immune system markers, and participants filled out a questionnaire about their quality of life. Around halfway through the study, there was a short phone call to check how things were going and ask about any side effects.

What are the possible benefits and risks of participating?

Participants might experience better wellbeing and improved immune function, although this isn't guaranteed. The risks were very low and mostly limited to mild digestive discomfort.

Where is the study run from?

The study was led by two dermatologists, Dr Marina Corral and Dr Nuria Setó Torrent, at Hospital Universitari Sagrat Cor in Barcelona, Spain. It was coordinated by Methodex S.L., also based in Barcelona.

When is the study starting and how long is it expected to run for?
April 2021 to December 2022

Who is funding the study?
The study was sponsored by Nutris Ingredients S.L., a company based in Madrid, Spain.

Who is the main contact?
Dr Marina Corral, marina.corral@clinicadiagonal.com
Dr Nuria Setó Torrent, nurisetorrent@gmail.com

Contact information

Type(s)
Public, Scientific

Contact name
Dr Veronica Gallo

ORCID ID
<https://orcid.org/0000-0002-9738-608X>

Contact details
Calle Marzo 58
Madrid
Spain
28022
+34 692911819
vgallo@nutris.es

Type(s)
Principal investigator

Contact name
Dr Marina Corral

Contact details
CM Tarradellas. Av. de Josep Tarradellas, 33, Sants-Montjuic
Barcelona
Spain
08029
+34 637524625
marina.corral@clinicadiagonal.com

Type(s)
Principal investigator

Contact name
Dr Nuria Seto

ORCID ID

<https://orcid.org/0000-0001-7922-9905>

Contact details

Centro Mèdico FIATC Tarradellas. Av de Josep Tarradellas, 33
Barcelona
Spain
08029
+34 607488717
nurisetorrent@gmail.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Protocol serial number

MTH-NUT0121

Study information

Scientific Title

Prospective, double-blind, randomized, single-center pilot clinical study compared with placebo, to assess efficacy, safety and acceptability of a probiotic with *Bacillus coagulans* on immunomodulation in healthy volunteers

Study objectives

The main objective of this study was to assess the efficacy, safety, and acceptability of an oral probiotic containing *Bacillus coagulans* on Immunomodulation in healthy adults compared with placebo.

Primary hypothesis: Oral administration of *Bacillus coagulans* exerts an immunomodulatory effect compared with placebo.

Secondary hypotheses: Oral administration of *Bacillus coagulans* improves quality of life and it is safe and well-tolerated without adverse effects compared with placebo.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 14/09/2021, CEIm Grupo Hospitalario Quirónsalud-Catalunya (Carrer de Pedro i Pons, 1, Sant Cugat del Vallès, Barcelona, 08195, Spain; +34 935656000; ceic.idcsa.cat@idcsalud.es), ref: 2021/81-DER-HUSC

Study design

Randomized placebo-controlled double-blind parallel groups (1:1 allocation)

Primary study design

Interventional

Study type(s)

Efficacy, Quality of life, Safety

Health condition(s) or problem(s) studied

Immune modulation and quality of life in healthy adults.

Interventions

Participants are randomly assigned (1:1) to receive either the probiotic product or a placebo for 90 days. The experimental group receives one oral capsule daily before meals containing *Bacillus coagulans* (5×10^9 CFU/day). The control group receives one identical placebo capsule daily with the same appearance and schedule. All participants attend two on-site visits (Day 1 and Day 90) at Hospital Universitari Sagrat Cor for blood sample collection and quality-of-life assessment. A telephone follow-up is performed at mid-study (around Day 45) to monitor adherence and safety.

The randomisation process was computer-generated using R statistical software (RStudio) prior to enrolment. Participants were then assigned in a 1:1 ratio to either the probiotic or placebo group according to this pre-established randomisation list. The allocation was implemented by the CRO (Methodex SL), ensuring double-blind conditions for investigators and participants throughout the study.

Intervention Type

Supplement

Primary outcome(s)

Levels of immunological markers (immunoglobulin A [IgA], immunoglobulin G [IgG], interferon- γ [IFN- γ], and total leukocyte count) measured by blood analysis at baseline (Day 1) and after 90 days of supplementation (Day 90)

Key secondary outcome(s)

1. Health-related quality of life measured using the SF-36 questionnaire at baseline (Day 1) and after 90 days of supplementation (Day 90)
2. Safety and tolerability assessed through participant reports and clinical evaluation at each visit and via follow-up phone call (around Day 45)

Completion date

29/12/2022

Eligibility

Key inclusion criteria

1. Healthy male and female volunteers aged 18–65 years
2. Individuals following a balanced diet according to standard nutritional guidelines
3. Participants performing at least 30 minutes of daily physical activity
4. Good personal hygiene and general health status
5. No psychological or psychiatric disorders
6. No family history of genetically heritable diseases
7. Able to understand the study information and comply with study requirements
8. Willing to provide written informed consent before participation

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

65 years

Sex

All

Total final enrolment

55

Key exclusion criteria

1. Diagnosis of diabetes mellitus
2. Pregnant or breastfeeding women
3. Presence of autoimmune disease (e.g. Addison's disease, celiac disease, Graves' disease, Hashimoto's thyroiditis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, type I diabetes, etc.)
4. Current or recent treatment with immunosuppressive drugs
5. Presence of any chronic disease or acute respiratory infection (including common cold, flu, or COVID-19).
6. Use of antibiotics within 10 days prior to study start
7. Intake of probiotics or immune-boosting supplements (e.g. vitamin C, echinacea, royal jelly, multivitamins) within 10 days prior to study start
8. History of drug, alcohol, or substance abuse
9. Participation in another clinical trial within the previous 3 months
10. Any medical or social condition that, in the investigator's opinion, could interfere with study participation or data reliability

Date of first enrolment

17/11/2021

Date of final enrolment

29/03/2022

Locations**Countries of recruitment**

Spain

Study participating centre
Hospital Universitari Sagrat Cor – Department of Dermatology
c/ Viladomat 288, 5^a planta
Barcelona
Spain
08029

Sponsor information

Organisation
Nutris We Care About You

Funder(s)

Funder type
Not defined

Funder Name
Nutris We Care About You

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from Veronica Gallo (vgallo@nutris.es).

IPD sharing plan summary

Available on request